Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics : a prospective cohort study

Tools
- Tools
+ Tools

UK Coronavirus Cancer Monitoring Project Team (Including:

Lee, Lennard Y. W., Cazier, Jean-Baptiste, Starkey, Thomas, Briggs, Sarah E. W., Arnold, Roland, Bisht, Vartika, Booth, Stephen, Campton, Naomi A., Cheng, Vinton W. T., Collins, Graham et al.
). (2020) COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics : a prospective cohort study. The Lancet Oncology . doi:10.1016/S1470-2045(20)30442-3 (In Press)

[img]
Preview
PDF
WRAP-COVID-19-cancer-patients-primary-tumour-demographics-Briggs-2020.pdf - Accepted Version - Requires a PDF viewer.
Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0.

Download (1595Kb) | Preview
Official URL: https://doi.org/10.1016/S1470-2045(20)30442-3

Request Changes to record.

Abstract

Background
Patients with cancer are purported to have poor COVID-19 outcomes. However, cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour subtypes. The aim of this study was to investigate COVID-19 risk according to tumour subtype and patient demographics in patients with cancer in the UK.

Methods
We compared adult patients with cancer enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) cohort between March 18 and May 8, 2020, with a parallel non-COVID-19 UK cancer control population from the UK Office for National Statistics (2017 data). The primary outcome of the study was the effect of primary tumour subtype, age, and sex and on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence and the case–fatality rate during hospital admission. We analysed the effect of tumour subtype and patient demographics (age and sex) on prevalence and mortality from COVID-19 using univariable and multivariable models.

Findings
319 (30·6%) of 1044 patients in the UKCCMP cohort died, 295 (92·5%) of whom had a cause of death recorded as due to COVID-19. The all-cause case–fatality rate in patients with cancer after SARS-CoV-2 infection was significantly associated with increasing age, rising from 0·10 in patients aged 40–49 years to 0·48 in those aged 80 years and older. Patients with haematological malignancies (leukaemia, lymphoma, and myeloma) had a more severe COVID-19 trajectory compared with patients with solid organ tumours (odds ratio [OR] 1·57, 95% CI 1·15–2·15; p<0·0043). Compared with the rest of the UKCCMP cohort, patients with leukaemia showed a significantly increased case–fatality rate (2·25, 1·13–4·57; p=0·023). After correction for age and sex, patients with haematological malignancies who had recent chemotherapy had an increased risk of death during COVID-19-associated hospital admission (OR 2·09, 95% CI 1·09–4·08; p=0·028).

Interpretation
Patients with cancer with different tumour types have differing susceptibility to SARS-CoV-2 infection and COVID-19 phenotypes. We generated individualised risk tables for patients with cancer, considering age, sex, and tumour subtype. Our results could be useful to assist physicians in informed risk–benefit discussions to explain COVID-19 risk and enable an evidenced-based approach to national social isolation policies.

Item Type: Journal Article
Subjects: R Medicine > RA Public aspects of medicine
Divisions: Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): COVID-19 (Disease), Cancer
Journal or Publication Title: The Lancet Oncology
Publisher: The Lancet Publishing Group
ISSN: 1470-2045
Official Date: 2020
Dates:
DateEvent
2020Published
24 August 2020Available
24 August 2020Accepted
Date of first compliant deposit: 8 September 2020
DOI: 10.1016/S1470-2045(20)30442-3
Status: Peer Reviewed
Publication Status: In Press
Access rights to Published version: Open Access
Copyright Holders: © 2020 Elsevier Ltd. All rights reserved.
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
UNSPECIFIEDUniversity Of Birminghamhttp://dx.doi.org/10.13039/501100000855
UNSPECIFIEDUniversity Of Oxfordhttp://dx.doi.org/10.13039/501100000769

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us